Proactiveinvestors United Kingdom RNS press releases https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom RNS press releases RSS feed en Wed, 26 Jun 2019 20:49:06 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Breztri Aerosphere (PT010) approved in Japan for ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115854 Wed, 19 Jun 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115854 <![CDATA[RNS press release - Bevespi Aerosphere approved by the Japanese ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115843 Wed, 19 Jun 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115843 <![CDATA[RNS press release - Lynparza approved in Japan for 1st-line ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115845 Wed, 19 Jun 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190619070004_14115845 <![CDATA[RNS press release - Lynparza approved in the EU for 1st-line ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190618070012_14114121 Tue, 18 Jun 2019 07:00:12 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190618070012_14114121 <![CDATA[RNS press release - Calquence significantly prolonged the time patient ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190617070006_14112397 Mon, 17 Jun 2019 07:00:06 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190617070006_14112397 <![CDATA[RNS press release - Publication of a Prospectus ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190612164504_14108763 Wed, 12 Jun 2019 16:45:04 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190612164504_14108763 <![CDATA[RNS press release - Calquence Phase III ELEVATE-TN trial met primary ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190606070007_14100510 Thu, 06 Jun 2019 07:00:07 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190606070007_14100510 <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603150005_14096602 Mon, 03 Jun 2019 15:00:05 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603150005_14096602 <![CDATA[RNS press release - Block listing Interim Review ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603150005_14096607 Mon, 03 Jun 2019 15:00:05 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603150005_14096607 <![CDATA[RNS press release - Lynparza nearly doubled time patients lived with ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603070009_14095174 Mon, 03 Jun 2019 07:00:09 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190603070009_14095174 <![CDATA[RNS press release - Pooled analyses of the roxadustat global Phase III ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190510070005_14069037 Fri, 10 May 2019 07:00:05 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190510070005_14069037 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508140001_14066832 Wed, 08 May 2019 14:00:01 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508140001_14066832 <![CDATA[RNS press release - Director Declaration ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508110002_14066571 Wed, 08 May 2019 11:00:02 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508110002_14066571 <![CDATA[RNS press release - Trastuzumab deruxtecan demonstrated clinically ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508070004_14065640 Wed, 08 May 2019 07:00:04 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190508070004_14065640 <![CDATA[RNS press release - Calquence PhIII ASCEND trial met primary endpoint ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190507070008_14063804 Tue, 07 May 2019 07:00:08 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190507070008_14063804 <![CDATA[RNS press release - Qternmet XR approved in the US for type-2 diabetes ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190503070003_14061755 Fri, 03 May 2019 07:00:03 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190503070003_14061755 <![CDATA[RNS press release - Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190501150002_14059789 Wed, 01 May 2019 15:00:02 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190501150002_14059789 <![CDATA[RNS press release - Director/PDMR Shareholding ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190501120001_14059493 Wed, 01 May 2019 12:00:01 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190501120001_14059493 <![CDATA[RNS press release - Lynparza receives positive EU CHMP opinion for 1st ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190429070018_14054573 Mon, 29 Apr 2019 07:00:18 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190429070018_14054573 <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190426174523_14054350 Fri, 26 Apr 2019 17:45:23 +0100 https://www.proactiveinvestors.co.uk/LON:AZN/AstraZeneca/rns/LSE20190426174523_14054350